MedTrace Logo

P3 Long Term Safety Study of Once Daily SB204 in Acne

NCT02798120 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 601

Last updated 2023-05-12

Study results available
· View outcomes & findings →

Summary

This is a multi-center, open label long-term safety (LTS) study to be conducted in approximately 600 subjects with acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

DRUG

SB204 4%

Open label, topical SB204 4%

Sponsors & Collaborators

  • Chiltern International Inc.

    collaborator INDUSTRY

  • Novan, Inc.

    lead INDUSTRY

Principal Investigators

  • Joyce Rico · Novan, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
9 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-12
Primary Completion
2017-04-30
Completion
2017-04-27

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02798120 on ClinicalTrials.gov